124 related articles for article (PubMed ID: 34265509)
1. A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer.
Wang X; Bera K; Barrera C; Zhou Y; Lu C; Vaidya P; Fu P; Yang M; Schmid RA; Berezowska S; Choi H; Velcheti V; Madabhushi A
EBioMedicine; 2021 Jul; 69():103481. PubMed ID: 34265509
[TBL] [Abstract][Full Text] [Related]
2. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
[TBL] [Abstract][Full Text] [Related]
3. Computerized tumor multinucleation index (MuNI) is prognostic in p16+ oropharyngeal carcinoma.
Koyuncu CF; Lu C; Bera K; Zhang Z; Xu J; Toro P; Corredor G; Chute D; Fu P; Thorstad WL; Faraji F; Bishop JA; Mehrad M; Castro PD; Sikora AG; Thompson LD; Chernock RD; Lang Kuhs KA; Luo J; Sandulache V; Adelstein DJ; Koyfman S; Lewis JS; Madabhushi A
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651718
[TBL] [Abstract][Full Text] [Related]
4. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in Stage I, II resectable Non-Small Cell Lung Cancer: a retrospective multi-cohort study for outcome prediction.
Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil P; Velu P; Rajiah P; Gilkeson R; Feldman M; Choi H; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 32123864
[TBL] [Abstract][Full Text] [Related]
5. A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study.
Lu C; Bera K; Wang X; Prasanna P; Xu J; Janowczyk A; Beig N; Yang M; Fu P; Lewis J; Choi H; Schmid RA; Berezowska S; Schalper K; Rimm D; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Nov; 2(11):e594-e606. PubMed ID: 33163952
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.
Miura N; Kamita M; Kakuya T; Fujiwara Y; Tsuta K; Shiraishi H; Takeshita F; Ochiya T; Shoji H; Huang W; Ohe Y; Yamada T; Honda K
Oncotarget; 2016 May; 7(22):33165-78. PubMed ID: 27121206
[TBL] [Abstract][Full Text] [Related]
8. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
9. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.
Tang H; Xiao G; Behrens C; Schiller J; Allen J; Chow CW; Suraokar M; Corvalan A; Mao J; White MA; Wistuba II; Minna JD; Xie Y
Clin Cancer Res; 2013 Mar; 19(6):1577-86. PubMed ID: 23357979
[TBL] [Abstract][Full Text] [Related]
10. Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study.
Khorrami M; Bera K; Leo P; Vaidya P; Patil P; Thawani R; Velu P; Rajiah P; Alilou M; Choi H; Feldman MD; Gilkeson RC; Linden P; Fu P; Pass H; Velcheti V; Madabhushi A
Lung Cancer; 2020 Apr; 142():90-97. PubMed ID: 32120229
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10.
Grieve S; Ding K; Moore J; Finniss M; Ray A; Lees M; Hossain F; Murugesan A; Agar J; Acar C; Taylor J; Shepherd FA; Reiman T
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32220948
[TBL] [Abstract][Full Text] [Related]
12. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
Zhang N; Liang R; Gensheimer MF; Guo M; Zhu H; Yu J; Diehn M; Loo BW; Li R; Wu J
Theranostics; 2020; 10(25):11707-11718. PubMed ID: 33052242
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.
Chen DT; Hsu YL; Fulp WJ; Coppola D; Haura EB; Yeatman TJ; Cress WD
J Natl Cancer Inst; 2011 Dec; 103(24):1859-70. PubMed ID: 22157961
[TBL] [Abstract][Full Text] [Related]
15. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Effect of Lymphovascular Invasion on TNM Staging in Stage I Non-Small-cell Lung Cancer.
Noma D; Inamura K; Matsuura Y; Hirata Y; Nakajima T; Yamazaki H; Hirai Y; Ichinose J; Nakao M; Ninomiya H; Mun M; Nakagawa K; Masuda M; Ishikawa Y; Okumura S
Clin Lung Cancer; 2018 Jan; 19(1):e109-e122. PubMed ID: 29066222
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
[TBL] [Abstract][Full Text] [Related]
18. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
Der SD; Sykes J; Pintilie M; Zhu CQ; Strumpf D; Liu N; Jurisica I; Shepherd FA; Tsao MS
J Thorac Oncol; 2014 Jan; 9(1):59-64. PubMed ID: 24305008
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with positive pleural lavage cytology findings.
Ogawa H; Uchino K; Tanaka Y; Shimizu N; Okuda Y; Tane K; Tauchi S; Nishio W; Maniwa Y; Yoshimura M
Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):34-9. PubMed ID: 25911680
[TBL] [Abstract][Full Text] [Related]
20. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
